Q-omics provides the consensus-scored TUBGCP3 profile across patient tissues and cancer cell-line models. TUBGCP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TUBGCP3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TUBGCP3 protein abundance shows 25,856 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where TUBGCP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBGCP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBGCP3 survival associations across molecular data types. TUBGCP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBGCP3 RNA expression–survival associations across cancer types. High TUBGCP3 expression shows unfavorable associations in ACC, BLCA and UVM, but favorable associations in KIRC, UCS and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TUBGCP3 RNA expression.
This table summarizes TUBGCP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TUBGCP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBGCP3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, HNSC, STAD and KIRC. The COAD box plot shows higher TUBGCP3 RNA expression in tumor versus normal tissue (log2 FC = +1.237, t-test p < 0.001).
This table shows molecular features associated with TUBGCP3 in patient tissues and cancer cell lines. In patient samples, TUBGCP3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBGCP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
